|
|
| | NLRP3-IN-37 Basic information |
| Product Name: | NLRP3-IN-37 | | Synonyms: | NLRP3-IN-37;Phenol, 2-[8-[(3aS,7aR)-octahydro-6-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl]pyrido[2,3-d]pyridazin-5-yl]-5-(trifluoromethyl)- | | CAS: | 3033054-51-9 | | MF: | C22H22F3N5O | | MW: | 429.44 | | EINECS: | | | Product Categories: | | | Mol File: | 3033054-51-9.mol |  |
| | NLRP3-IN-37 Chemical Properties |
| Boiling point | 586.0±50.0 °C(predicted) | | density | 1.350±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 6.94±0.40(predicted) |
| | NLRP3-IN-37 Usage And Synthesis |
| Uses | NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury[1]. | | References | [1] Donna A. A, et al. WPhthalazine derivatives useful as inhibitors of nod-like receptor protein 3. Patent.WO2024064245A1. |
| | NLRP3-IN-37 Preparation Products And Raw materials |
|